1:45 PM (PT)
-
In vivo hematopoietic stem cell (HSC) engineering represents the next inflection point in genetic medicine - moving beyond transient delivery or ex vivo manipulation to direct, permanent reprogramming ...Breakout Session
-
Cell and Gene Therapy and Genome Editing
-
)
)
)
)
3:00 PM (PT)
-
For the first time in history, a patient has survived more than eight months following a gene-edited pig organ transplant, marking a pivotal moment as xenotransplantation moves from experimental promi ...Breakout Session
-
Next Generation Biotherapeutics
-
)
)
)
)
)
4:15 PM (PT)
-
This session will feature a Fireside Chat with the former CEOand CBO of Capstan Therapeutics, as they share firsthand experience leading Capstan through one of the marquee M&A deals of 2025, a $2B+ ac ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
For decades, the biotech innovation engine has produced extraordinary breakthroughs in cancer, rare diseases, and metabolic disorders. Yet across vast areas of medicine from preeclampsia to sarcopenia ...Breakout Session
- Next Generation Biotherapeutics
-
-
Cardiovascular disease (CVD) remains the world’s leading cause of death, yet policy prioritization and investment continue to lag behind its health and economic impact. This session will explore how g ...Breakout Session
- Next Generation Biotherapeutics
-
)
)
)
)
)
)
)
)
)
11:00 AM (PT)
-
This session will explore the critical journey of translating a scientific concept into a viable CNS therapeutic. Industry leaders will discuss the primary challenges and emerging solutions in neurosc ...Breakout Session
-
Brain Health
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
11:10 AM (PT)
-
Chiromesh Therapeutics is a biotechnology company developing innovative solutions for localized, sustained drug delivery in solid tumors. The company’s lead platform, μMESH, is a conformable, micro-st ...Start-Up Stadium Session
-
Oncology
-
11:20 AM (PT)
-
Palo Alto Immunotherapeutics (PAI) is developing advanced immunotherapies for the treatment of cancer. Cancer vaccines have centered around identifying mutant proteins as the target with little regard ...Start-Up Stadium Session
- Oncology
-
11:30 AM (PT)
11:40 AM (PT)
-
Montani Bio is a WV-based vaccines and therapeutics company focused on the expansion of the mRNA platform into new areas of disease. The company spun out of the Vaccine Development Center at West Virg ...Start-Up Stadium Session
- Oncology
-
11:55 AM (PT)
-
Sift is a preclinical-stage biotechnology company using AI and high-throughput T-cell screening to develop peptide immunotherapies for cancer and autoimmune disease. Founded in 2024 as a UC Berkeley s ...Start-Up Stadium Session
- Oncology
-
12:10 PM (PT)
-
TippingPoint Biosciences is building the first scalable platform to model disease-specific epigenetic states and systematically discover small molecules that selectively kill cells driven by inappropr ...Start-Up Stadium Session
- Oncology
-
12:20 PM (PT)
-
Ypsilon Therapeutics is expanding the reach of antibody therapeutics. Ypsilon is advancing a new class of cancer therapies with TCR mimics (TCRm), designed to address unmet needs in solid tumors. TCRm ...Start-Up Stadium Session
- Oncology
-
12:30 PM (PT)
-
Apmonia Therapeutics is a clinical-stage biotechnology company developing first-in-class peptide therapeutics targeting extracellular matrix signaling and the tumor microenvironment. Our lead program, ...Start-Up Stadium Session
- Oncology
-
12:45 PM (PT)
-
CNCure Co., Ltd. is a South Korea–based biotechnology company headquartered in Hwasun-gun, Jeonnam, focusing on cancer theranostics that combine therapy and diagnostics for precision medicine. The com ...Start-Up Stadium Session
- Oncology
-
1:45 PM (PT)
-
Central Nervous System (CNS) disorders remain among the most complex and urgent challenges in global healthcare. This session will spotlight the latest advancements in CNS research and development, hi ...Breakout Session
- Brain Health
-
-
Precision medicine has transformed oncology, but the next wave is unfolding in new therapeutic areas. The expansion into new areas promises enormous impact, yet the path forward is not straightforward ...Breakout Session
-
Diagnostics and Personalized Medicine
-
-
Rare diseases collectively affect more than 300 million people worldwide, yet fewer than 5% have an approved treatment. As cell and gene therapies (CGTs) progress from scientific aspiration to commerc ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
2:05 PM (PT)
2:20 PM (PT)
-
Voro Therapeutics is a privately held biotechnology company based in San Diego, spun out of Alloy Therapeutics’ 82VS Venture Studio. The company’s PrimeBody platform is a best-in-class conditionally-a ...Start-Up Stadium Session
- Oncology
-
2:30 PM (PT)
3:00 PM (PT)
-
Intelligence Precision Medicine cannot achieve its promise if entire populations remain underrepresented in the data that fuels it. As multiomic and real-world datasets expand, the next wave of therap ...Breakout Session
- Diagnostics and Personalized Medicine
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
4:15 PM (PT)
-
The metabolic disease treatment landscape is transforming rapidly. While GLP-1 receptor agonists have demonstrated remarkable efficacy, addressing the full scope of metabolic dysfunction requires ther ...Breakout Session
- Next Generation Biotherapeutics
-
-
For years, therapeutic development for Alzheimer’s and other neurodegenerative diseases has focused on the pathologies within the brain such as, in the case of Alzheimer’s, amyloid plaques and tau tan ...Breakout Session
- Brain Health
-
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
11:00 AM (PT)
-
As diagnostics and precision medicine continue to advance, companies developing novel diagnostic technologies, analytical tools, and data-enabled testing solutions are reshaping how disease is detecte ...Breakout Session
- Diagnostics and Personalized Medicine
-
-
Overall survival (OS) remains the gold standard endpoint in oncology trials, but the FDA’s August 2025 draft guidance highlights new complexities in assessing survival in an era of highly effective th ...Breakout Session
- Oncology
-
)
)
)
)
)
)
11:10 AM (PT)
11:20 AM (PT)
-
Coastar Therapeutics is a venture-backed biotech firm headquartered in San Diego, CA, dedicated to advancing next-generation gene delivery technology. The company has developed a novel eLNP technology ...Start-Up Stadium Session
- Cell and Gene Therapy and Genome Editing
-
11:30 AM (PT)
-
153 Therapeutics is a UCSF spinout developing a novel small-molecule therapy for Parkinson’s Disease. The approach targets Nurr1, a nuclear receptor that plays a central role in restoring dopamine pro ...Start-Up Stadium Session
- Brain Health
-
11:40 AM (PT)
-
BrainStorm Therapeutics is a precision neuroscience company developing disease-modifying therapies for rare and neurodegenerative brain disorders. We integrate patient-derived brain organoids with AI ...Start-Up Stadium Session
- Brain Health
-
11:55 AM (PT)
12:10 PM (PT)
12:20 PM (PT)
12:30 PM (PT)
-
Sculpta, Inc. is a San Francisco based startup founded by physician scientist and former Stanford faculty member Neal Amin. Sculpta is pioneering Protein Sculpting therapeutics, splice-switching antis ...Start-Up Stadium Session
- Brain Health
-
12:45 PM (PT)
-
Zena Therapeutics is developing safer alternatives to benzodiazepines by leveraging a novel GABA-A receptor binding site. Our partial positive allosteric modulators (PAMs) deliver anxiolytic and anti- ...Start-Up Stadium Session
- Brain Health
-
1:45 PM (PT)
-
Longevity science has entered its execution era. What once sounded speculative now rests on clearer biology, richer human datasets, and maturing toolkits that are pushing longevity from buzzword to bu ...Breakout Session
- Next Generation Biotherapeutics
-
-
Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, ...Breakout Session
- Oncology
-
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
3:00 PM (PT)
-
For 87 years, our industry had to operate under an uncomfortable truth: over 90% of cancer drugs that "cure" mice routinely fail patients in clinical trials. In 2022, the FDA Modernization Act 2.0 too ...Breakout Session
- Oncology
-
-
For decades, autoimmune disease therapy has been defined by one trade-off - suppressing the immune system to relieve symptoms. That paradigm is now breaking. The 2025 Nobel Prize in Physiology of Medi ...Breakout Session
- Next Generation Biotherapeutics
-
-
Inherited Retinal Diseases (IRDs) were once considered untreatable, leaving patients and families facing the certainty of progressive vision loss. Today, advances in gene therapy are changing that rea ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
4:15 PM (PT)
-
The advances in technology over the past decade have yielded a broad range of biologics for cancer, each with unique attributes. This is great news for patients to have so many tools in the toolkit, b ...Breakout Session
- Oncology
-
-
Long-term post-marketing safety monitoring is crucial for understanding the risks of new therapies in real-world settings, yet current registries often create considerable burdens without delivering r ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
The FDA’s new guidance supporting non-animal testing methods is reshaping preclinical drug development, creating unprecedented opportunities for biotech innovation. This session brings together biotec ...Breakout Session
- Next Generation Biotherapeutics
-
-
Heart disease remains the leading cause of death in the United States, with a person dying every 34 seconds from cardiovascular disease, claiming almost one million American lives every year and accou ...Breakout Session
- Next Generation Biotherapeutics
-
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
9:00 AM (PT)
-
Long before immunotherapy took center stage, it lived on the margins of oncology. Those pursuing it were often politely dismissed as “dreamers,” relegated to the back rooms at ASCO as well-intentioned ...Breakout Session
- Oncology
-
-
CAR-T cell therapy has fundamentally transformed outcomes for patients with certain hematologic malignancies and, increasingly, solid tumors — yet the vast majority of eligible patients never receive ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
Over the past five decades, the Langer Lab has played a central role in shaping modern biotechnology—founding more than 40 companies and training over 1,000 scientists, many of whom are now professors ...Breakout Session
- Next Generation Biotherapeutics
-
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
.jpeg)
)
10:15 AM (PT)
-
Cell and gene therapies have become invaluable modalities in the medicine toolkit. Following recent safety concerns with AAV vector technology, experts will look increasingly toward new vectors and de ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
Antibody–drug conjugates (ADCs) reshaped cancer treatment by combining the precision of targeted antibodies with the potency of cytotoxic therapies, but as the field matures, the focus is shifting tow ...Breakout Session
- Oncology
-
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}